Capital Research Global Investors Buys 95,944 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Capital Research Global Investors lifted its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 7.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,400,559 shares of the life sciences company's stock after buying an additional 95,944 shares during the quarter. Capital Research Global Investors owned about 1.82% of Integra LifeSciences worth $31,765,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Norges Bank acquired a new stake in Integra LifeSciences in the 4th quarter worth approximately $8,967,000. Access Investment Management LLC acquired a new stake in Integra LifeSciences in the 4th quarter worth approximately $4,416,000. Cannell & Spears LLC acquired a new stake in Integra LifeSciences in the 4th quarter worth approximately $3,555,000. First Trust Advisors LP lifted its holdings in Integra LifeSciences by 319.7% in the 4th quarter. First Trust Advisors LP now owns 186,300 shares of the life sciences company's stock worth $4,225,000 after purchasing an additional 141,907 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Integra LifeSciences by 130.5% in the 4th quarter. JPMorgan Chase & Co. now owns 199,691 shares of the life sciences company's stock worth $4,529,000 after purchasing an additional 113,061 shares during the last quarter. Institutional investors own 84.78% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Truist Financial reduced their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $22.71.

Integra LifeSciences Stock Performance

Shares of IART traded up $0.11 on Friday, reaching $16.81. 758,558 shares of the stock traded hands, compared to its average volume of 1,038,451. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -186.76, a P/E/G ratio of 0.73 and a beta of 1.24. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 12 month low of $14.45 and a 12 month high of $32.66. The stock's 50-day moving average price is $20.51 and its 200-day moving average price is $22.23.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. The business had revenue of $442.65 million for the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences's quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.89 earnings per share. Equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.